Compare Aurora Cannabis Inc (ACB) vs TeraWulf Inc (WULF) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

WULF trades at $22.21, up 4.86% with strong analyst support despite bearish technical signals. The company recently secured a transformative $19 billion AI infrastructure deal with Anthropic, shifting focus from Bitcoin mining to long-term contracted revenue. However, fundamentals show significant challenges with negative profit margins (-611.46%) and high valuation ratios (P/S 53.86, P/B 84.25) amid consecutive earnings misses.

The outlook balances substantial AI opportunity against current financial weakness. The 20-year Anthropic contract provides revenue visibility, but execution risks and negative cash flow from operations (-$123M) require careful monitoring. With 100% analyst buy ratings and $32.40 consensus target offering 46% upside, the stock presents high-risk, high-reward potential for investors believing in the AI infrastructure pivot.